Chronic Fatigue Syndrome Patients Need an Effective Therapeutic, Leading Expert Argues | Science Daily | 24 January 2013

January 28, 2013


From Science Daily, 24 January 2013.

Ampligen, the first drug ever seeking approval to treat chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), recently hit another roadblock with the U.S. Food and Drug Administration (FDA). In its long quest to treat 1 million Americans suffering from this debilitating illness, the FDA advisory panel did not recommend the drug to be sold on the market, largely because CFS/ME doesn't have clear biomarkers such as blood tests to define patients who most likely to respond to the drug. Data from clinical trials of Ampligen has not convinced the FDA so far.

Nancy Klimas, M.D., one of the world’s leading researchers and clinicians in chronic fatigue syndrome/myalgic encepahalomyelitis (CFS/ME), is the director the NSU Institute for Neuro Immune Medicine. “The real loser is not Ampligen, but CFS/ME patients whose daily suffering continues to be unabated,” she says. “CFS/ME feels like you've been run over by a truck — pain, inflammation, utter exhaustion and trouble concentrating.”

Klimas has been caring for patients with CFS/ME for 26 years now. “It's heartbreaking seeing them struggle and suffer from this serious illness that has been trivialized by science and society. One of the early controversies quickly disproven suggested that CFS/ME is a form of depression. This led to enduring public policies that allowed insurance companies to limit coverage to CFS/ME to either mental health or exercise therapy, neither get to the root cause of CFS/ME,” she explains.

“CFS/ME researchers, including myself, have seen major advances in our understanding of the biology of CFS/ME. It seems to resemble an illness we know how to treat like multiple sclerosis (MS), chronic viral diseases and autoimmune diseases.”

Around since the late 1980s, this drug is not new to science and medicine. Two phase 3 clinical studies have been completed. The data shows that a subgroup of CFS/ME patients showed marked improvement, even recovery on the drug.

“Yet, that's not enough evidence for the FDA advisory committee to approve because they would like to see a conclusive biomarker,” notes Klimas. “As a physician, I could live with this decision if I had other effective therapies to treat my CFS/ME patients. But I do not. Moreover, it defies common logic in used in drug approval for other complex immune mediated diseases.”

Take for example, MS: Its earliest approved treatments had opposite immune effects. One interferon increased immune activity and a second interferon quieted immune activity. In the studies that led to approval, MS drugs, like Ampligen, had about a 40 percent success rate.

Clinical research for these early MS drugs produced no biomarkers other than a patient's successful response to therapy, such as the case of Ampligen. The biomarker the FDA relied on for approval of MS — seeing if the lesions in a patient's brain decreased — had no correlation to the patient's improvement.

Why would the FDA approve MS drugs before there were concrete biomarkers to determine success? The answer is simple, Klimas says. The advisory panel saw MS as a serious disease that required interventions ASAP, and were willing to accept that clinicians would better understand where to use the first drugs with more experience using them. Now there are seven approved drugs for MS that have significantly improved quality of life for patients. But they are not willing to use the same logic for Ampligen.

“With or without a biomarker, the FDA should recognize the seriousness of CFS/ME and approve Ampligen, and open the door for other targeted therapies now,” she says.

2 thoughts on “Chronic Fatigue Syndrome Patients Need an Effective Therapeutic, Leading Expert Argues | Science Daily | 24 January 2013”

  1. I am puzzled as to how Nancy Klimas has concluded that Ampligen wasn’t approved because “CFS/ME doesn’t have clear biomarkers”. This won’t be the reason as there can be no disease which would encompass fatigue syndrome (F48.0) and ME (93.3), which Oxford, Fukuda, Reeves, CCC and ICC, undoubtably do. Fukuda and Reeves being the instruments that Klimas selects. The FDA has a long history of approving treatments for similar diseases to ME without any biomarker, as can be seen in approvals for the neuroimmune disease MS. If Klimas wishes to treat with Ampligen then perhaps a study showing that Ampligen is effective should be her next project. That would be the first step in gaining approval. Why complain but not have achieved this basic requirement? Klimas isn’t complaining that exercise hasn’t been approved but that too has no science study to confirm it is effective for ME.

  2. “Accentuate the positive, eliminate the negative,” as the song says.
    Nancy Klimas was researching (and treating) ME when such activity was definitely frowned upon by the scientific and medical establishments – good for her. We need many more like her.
    Keep up the good work Prof Klimas.

Comments are closed.

Shopping Cart